We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Smart Patch Prevents Fatal Blood Clots in Mouse Model

By Gerald M. Slutzky, PhD
Posted on 09 Dec 2016
Tests on a mouse model of thrombosis showed that a novel "smart patch" heparin delivery system prevented clotting efficiently in a feedback-controlled manner.

An interdisciplinary team of researchers at North Carolina State University (Raleigh, USA) and the University of North Carolina (Chapel Hill, USA) had designed a smart patch comprising microneedles made of a polymer composed of hyaluronic acid (HA) and heparin.

The polymer was designed to be responsive to thrombin, an enzyme that initiates clotting in the blood. More...
Elevated levels of thrombin in the bloodstream dissolved the amino acid chains binding heparin to HA, releasing the heparin into the blood stream.

In a paper published in the November 25, 2016, online edition of the journal Advanced Materials, the investigators described testing the smart patch on mice. Mice were either left untreated, injected with heparin, or treated with the HA-heparin smart patch 10 minutes or six hours before being injected with a lethal dose of thrombin.

All of the mice with the HA-heparin smart patch survived both treatments. Mice injected with heparin survived the 10-minute exposure, but around 80% died after six hours. All the untreated mice were killed by both treatments.

"Our goal was to generate a patch that can monitor a patient's blood and release additional drugs when necessary; effectively, a self-regulating system," said senior author Dr. Zhen Gu, assistant professor in the joint biomedical engineering program at North Carolina State University and the University of North Carolina. "We are excited about the possibility of using a closed-loop, self-regulating smart patch to help treat a condition that affects thousands of people every year, while hopefully also driving down treatment costs. This paper represents a good first step, and we are now looking for funding to perform additional preclinical testing."

Related Links:
North Carolina State University
University of North Carolina


New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
ESR Analyzer
TEST1 2.0
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.